Recent News Releases
For investor-related news, see our ASX releases here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Dec 12, 2017Dr Brian McNamee AO and Mr Abbas Hussain have been appointed as independent Non-Executive Directors, effective 14 February 2018. CSL (ASX:CSL; USOTC:CSLLY) today announced that Dr Brian McNamee AO...
Dec 11, 2017CSL Behring today announced that it has signed an agreement with the National Blood Authority, representing all Australian governments, to continue to provide the community with a world-class and...
Dec 7, 2017CSL today officially opened a new AUD$230 million advanced manufacturing facility at its CSL Behring site in Broadmeadows with the assistance of Victorian Minister for Industry and Employment, Ben...
-
Dec 5, 2017The two companies have entered into a strategic collaboration and purchase option agreement to expedite the development of clazakizumab (an anti-IL6 MAB, formerly ALD518) as a therapeutic option for solid organ transplant rejection.
05 Dec 2017 Melbourne, Australia and Vancouver, Canada: CSL Limited (ASX:CSL; USOTC:CSLLY) and Vitaeris Inc. (Vitaeris) today announced that they have entered into a strategic collaboration and...
Dec 5, 2017The study will be the largest ever undertaken by CSL, and will enroll more than 17,000 patients from approximately 1,000 sites around the world. Jemimah Pentland 05 Dec 2017 Global biotherapeutics...
-
Nov 23, 2017
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Nov 16, 2017
This decision comes after Public Health England declared that conventional non-adjuvanted influenza vaccines provided little or no protection for adults aged 65 years and over in the 2016-17 flu...
-
Nov 9, 2017Hizentra PATH study, the largest controlled clinical study in patients with CIDP, met its primary endpoint
09 Nov 2017 KING OF PRUSSIA, Pa. — 09 November 2017 Global biotherapeutics leader CSL Behring announced that results were published in The Lancet Neurology from its PATH study (Polyneuropathy...
-
Nov 8, 2017
Nearly a hundred new high tech jobs are to be created at the Liverpool manufacturing site of Seqirus as a result of major new investment announced today. 08 Nov 2017 New fill-and-finish facility...
-
Oct 29, 2017A subgroup analysis of data from the Phase III COMPACT trial showed 98 percent median reduction in hereditary angioedema (HAE) attacks per month in subjects who experienced at least one attack per week while on placebo
29 Oct 2017 KING OF PRUSSIA, Pa. — 29 October 2017 Global biotherapeutics leader CSL Behring today presented data indicating that, at the approved dose of 60 IU/kg, HAEGARDA® reduced the median...